[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337755-105":59,"doc-detail-337755-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","role-of-n6-methyladenosine-in-the-pathogenesis-diagnosis-and-treatment-of-prostate-cancer-review","Role of N6-methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer - Review","","Prostate cancer (PCa) affects men across races and ethnic groups and contributes to higher mortality in populations facing late detection and socioeconomic barriers. PCa most commonly involves men aged 45–60 and remains a leading cause of cancer-related death in Western countries. N6-methyladenosine (m6A) is the most abundant mRNA modification in higher eukaryotes and regulates mRNA metabolism. Abnormal m6A regulator expression can drive PCa development and progression. This review synthesizes current evidence on m6A regulatory factors in PCa pathogenesis, diagnosis, and therapy, highlighting micro-molecular epigenetic targeting of m6A regulators as a future direction.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/role-of-n6-methyladenosine-in-the-pathogenesis-diagnosis-and-treatment-of-prostate-cancer-review/337755/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/role-of-n6-methyladenosine-in-the-pathogenesis-diagnosis-and-treatment-of-prostate-cancer-review/337755.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What role does N6-methyladenosine (m6A) play in prostate cancer?","Question",{"text":113,"@type":114},"m6A is a widespread mRNA modification that regulates mRNA metabolism. Dysregulated expression of m6A regulators can significantly influence PCa development and progression.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the review describe PCa diagnosis and treatment challenges?",{"text":118,"@type":114},"Early-stage PCa may show subtle or asymptomatic signs and can be overlooked, contributing to late detection. Current diagnostic approaches are moving toward precision strategies informed by genetic testing.",{"name":120,"@type":111,"acceptedAnswer":121},"What future therapeutic direction does the review highlight for PCa?",{"text":122,"@type":114},"Targeting the epigenetics of m6A regulators with micro-molecular drugs to correct abnormal m6A modifications is presented as a direction for future diagnostic and therapeutic development.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},337755,1790125716,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","ONCOLOGY REPORTS 51: 88, 2024  \nRole of N6‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)  \nJUNJIE PAN 1,2* , FEI TONG3* , NING REN2 , LANQI REN2 , YIBEIYANG2 , FENG GAO4** and QIAOPING XU 1**  \n1Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province,  \nAffiliated Hangzhou First People's Hospital, Cancer Center, Westlake University School of Medicine, Hangzhou, Zhejiang 310006, 2  \nP.R. China; Fourth Clinical Medical College of Zhejiang Chinese Medical University, Affiliated Hangzhou First People's Hospital, Hangzhou,  \nZhejiang 310051, P.R. China; 3Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510280, 4  \nP.R. China; Department of Urology, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang 310007, P.R. China  \nReceived November 2, 2023; Accepted April 19, 2024  \nDOI: 10. 3892/or.2024.8747  \nAbstract. Prostate cancer (PCa) affects males of all racial and ethnic groups, and leads to higher rates of mortality in those belonging to a lower socioeconomic status due to the late detection of the disease. PCa affects middle‑aged males between the ages of 45 and 60 years, and is the highest cause of cancer‑associated mortality in Western countries. As the most abundant and common mRNA modification in higher eukaryotes, N6‑methyladenosine (m6A) is widely distributed in mammalian cells and influences various aspects of mRNA metabolism. Recent studies have found that abnormal expres‑ sion levels of various m6A regulators significantly affect the development and progression of various types of cancer, including PCa. The present review discusses the influence of m6A regulatory factors on the pathogenesis and progression of PCa through mRNA modification based on the current state of research on m6A methylation modification in PCa. It is considered that the treatment of PCa with micro‑molecular drugs that target the epigenetics of the m6A regulator to correct abnormal m6A modifications is a direction for future research into current diagnostic and therapeutic approaches for PCa.  \nCorrespondence to: Ms. Qiaoping Xu, Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Westlake University School of Medicine, 261 Huan Sha Road, Hangzhou, Zhejiang 310006, P.R. China  \nE‑mail: [xqp1984@126.com](xqp1984@126.com)  \nProfessor Feng Gao, Department of Urology, Hangzhou Hospital of Traditional Chinese Medicine, 453 Ti Yu Chang Road, Hangzhou, Zhejiang 310007, P.R. China  \nE‑mail: [friendgao@yeah.net](friendgao@yeah.net)  \n*,**Contributed equally  \nKey words: prostate cancer, N6‑methyladenosine, regulator, genetics, RNA  \nContents  \n1. Introduction  \n2. PCa  \n3. m6A  \n4. Role of m6A regulators in PCa  \n5. m6A and non‑coding RNA modifications  \n6. PCa and m6A  \n7. Conclusion and future perspectives  \n1. Introduction  \nPCa is the leading non‑cutaneous malignant tumors in males in China (1) . PCa is the most common type of cancer affecting males (20%) and accounts for 6. 8% of male cancer‑related deaths worldwide. According to statistics, in 2020, the number of new cases of PCa reached 1.41 million and caused 375,000 deaths . The number of new cases and deaths from PCa is expected to nearly double by the year 2040 (2) . In 2019, the number of cases of PCa in China reached 150,000 and there were 54,000 related deaths (3) . In recent years, technological progress and the development of new methods have largely led to an increased understanding of the underlying molecular mechanisms that promote tumor growth and progression (4) . The advent of current drug and therapy combinations has enriched the treatment options for PCa, providing more treat‑ ment options for patients with PCa (5) . However, there are certain challenges for clinical practitio","cbCaihA5Olv8u5DM","https://ap.wps.com/l/cbCaihA5Olv8u5DM","pdf",1653688,16,"English","# Contents\n## 1. Introduction\n## 2. PCa\n## 3. m6A\n## 4. Role of m6A regulators in PCa\n## 5. m6A and non-coding RNA modifications\n## 6. PCa and m6A\n## 7. Conclusion and future perspectives","[{\"question\":\"What role does N6-methyladenosine (m6A) play in prostate cancer?\",\"answer\":\"m6A is a widespread mRNA modification that regulates mRNA metabolism. Dysregulated expression of m6A regulators can significantly influence PCa development and progression.\"},{\"question\":\"How does the review describe PCa diagnosis and treatment challenges?\",\"answer\":\"Early-stage PCa may show subtle or asymptomatic signs and can be overlooked, contributing to late detection. Current diagnostic approaches are moving toward precision strategies informed by genetic testing.\"},{\"question\":\"What future therapeutic direction does the review highlight for PCa?\",\"answer\":\"Targeting the epigenetics of m6A regulators with micro-molecular drugs to correct abnormal m6A modifications is presented as a direction for future diagnostic and therapeutic development.\"}]","Role of N6-methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer - Review | PDF",1790020504]